blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3060580

EP3060580 - ANTI-PODOCALYXIN ANTIBODIES AND METHODS OF USING THE SAME [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  04.02.2022
Database last updated on 26.06.2024
FormerThe patent has been granted
Status updated on  26.02.2021
FormerGrant of patent is intended
Status updated on  14.10.2020
FormerExamination is in progress
Status updated on  02.03.2018
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Centre For Drug Research And Development
2405 Wesbrook Mall
Fourth Floor
Vancouver, British Columbia V6T 1Z3 / CA
For all designated states
University of British Columbia
2329 West Mall
Vancouver, British Columbia V6T 1Z4 / CA
[2016/35]
Inventor(s)01 / BABCOOK, John Stephen
4480 West 12th Ave
Vancouver, British Columbia V6R 2R2 / CA
02 / MCNAGNY, Kelly Marshall
2878 West 23rd Avenue
Vancouver, British Columbia V6L 1P3 / CA
03 / ROSKELLEY, Calvin D.
836 East 31st Ave
Vancouver, British Columbia V5V 2X1 / CA
04 / HEDBERG, Bradley John
4016 Glen Drive
Vancouver, British Columbia V5V 4T3 / CA
05 / SNYDER, Kimberly Ashely
210-2570 Hemlock Street
Vancouver, British Columbia V6H 2V4 / CA
06 / HUGHES, Michael R.
113-6279 Eagles Drive
Vancouver, British Columbia V6T 2K7 / CA
 [2016/35]
Representative(s)Secerna LLP
The Old Fire Station
18 Clifford Street
York YO1 9RD / GB
[2021/13]
Former [2016/35]Secerna LLP
The Catalyst
Baird Lane, Heslington East
York YO10 5GA / GB
Application number, filing date14856004.821.10.2014
[2016/35]
WO2014CA51020
Priority number, dateUS201361893817P21.10.2013         Original published format: US 201361893817 P
[2016/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015058301
Date:30.04.2015
Language:EN
[2015/17]
Type: A1 Application with search report 
No.:EP3060580
Date:31.08.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 30.04.2015 takes the place of the publication of the European patent application.
[2016/35]
Type: B1 Patent specification 
No.:EP3060580
Date:31.03.2021
Language:EN
[2021/13]
Search report(s)International search report - published on:CA30.04.2015
(Supplementary) European search report - dispatched on:EP28.02.2017
ClassificationIPC:C07K16/30, A61K39/395, A61P35/00, C07K16/28, C12N15/13, A61K39/00
[2017/13]
CPC:
C07K16/28 (EP,US); A61P35/00 (EP); C07K16/30 (EP,US);
A61K2039/505 (EP,US); C07K2317/20 (US); C07K2317/24 (EP,US);
C07K2317/33 (US); C07K2317/52 (US); C07K2317/56 (US);
C07K2317/565 (US); C07K2317/567 (US); C07K2317/73 (EP,US);
C07K2317/92 (EP,US) (-)
Former IPC [2016/35]C07K16/30, A61K39/395, A61P35/00, C07K16/28, C12N15/13
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/35]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ANTI-PODOCALYXIN-ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG DAVON[2016/35]
English:ANTI-PODOCALYXIN ANTIBODIES AND METHODS OF USING THE SAME[2016/35]
French:ANTICORPS ANTI-PODOCALYXINE ET LEURS MÉTHODES D'UTILISATION[2016/35]
Entry into regional phase13.05.2016National basic fee paid 
13.05.2016Search fee paid 
13.05.2016Designation fee(s) paid 
13.05.2016Examination fee paid 
Examination procedure13.05.2016Examination requested  [2016/35]
24.09.2017Amendment by applicant (claims and/or description)
02.03.2018Despatch of a communication from the examining division (Time limit: M06)
30.08.2018Reply to a communication from the examining division
21.09.2018Despatch of a communication from the examining division (Time limit: M06)
21.03.2019Reply to a communication from the examining division
11.09.2019Observations by third parties
16.10.2019Despatch of a communication from the examining division (Time limit: M06)
09.04.2020Reply to a communication from the examining division
15.10.2020Communication of intention to grant the patent
23.02.2021Fee for grant paid
23.02.2021Fee for publishing/printing paid
23.02.2021Receipt of the translation of the claim(s)
Opposition(s)04.01.2022No opposition filed within time limit [2022/10]
Fees paidRenewal fee
11.10.2016Renewal fee patent year 03
11.10.2017Renewal fee patent year 04
11.10.2018Renewal fee patent year 05
04.10.2019Renewal fee patent year 06
29.09.2020Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.10.2014
AL31.03.2021
AT31.03.2021
CY31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
GR31.03.2021
HR31.03.2021
IT31.03.2021
LT31.03.2021
LV31.03.2021
MC31.03.2021
MK31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SI31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
IE21.10.2021
LU21.10.2021
BE31.10.2021
CH31.10.2021
LI31.10.2021
[2024/22]
Former [2023/36]HU21.10.2014
AL31.03.2021
AT31.03.2021
CY31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
GR31.03.2021
HR31.03.2021
IT31.03.2021
LT31.03.2021
LV31.03.2021
MC31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SI31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
IE21.10.2021
LU21.10.2021
BE31.10.2021
CH31.10.2021
LI31.10.2021
Former [2023/30]HU21.10.2014
AL31.03.2021
AT31.03.2021
CY31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
IT31.03.2021
LT31.03.2021
LV31.03.2021
MC31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SI31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
IE21.10.2021
LU21.10.2021
BE31.10.2021
CH31.10.2021
LI31.10.2021
Former [2023/29]HU21.10.2014
AL31.03.2021
AT31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
IT31.03.2021
LT31.03.2021
LV31.03.2021
MC31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SI31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
IE21.10.2021
LU21.10.2021
BE31.10.2021
CH31.10.2021
LI31.10.2021
Former [2022/48]AL31.03.2021
AT31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
IT31.03.2021
LT31.03.2021
LV31.03.2021
MC31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SI31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
IE21.10.2021
LU21.10.2021
BE31.10.2021
CH31.10.2021
LI31.10.2021
Former [2022/37]AL31.03.2021
AT31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
IT31.03.2021
LT31.03.2021
LV31.03.2021
MC31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SI31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
LU21.10.2021
BE31.10.2021
CH31.10.2021
LI31.10.2021
Former [2022/36]AL31.03.2021
AT31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
IT31.03.2021
LT31.03.2021
LV31.03.2021
MC31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SI31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
LU21.10.2021
BE31.10.2021
Former [2022/35]AL31.03.2021
AT31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
MC31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SI31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
LU21.10.2021
BE31.10.2021
Former [2022/33]AL31.03.2021
AT31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
MC31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SI31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
BE31.10.2021
Former [2022/29]AL31.03.2021
AT31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SI31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
Former [2022/23]AL31.03.2021
AT31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
Former [2022/10]AL31.03.2021
AT31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
PT02.08.2021
IS24.12.2021
Former [2022/08]AL31.03.2021
AT31.03.2021
CZ31.03.2021
DK31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
Former [2022/07]AL31.03.2021
AT31.03.2021
CZ31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
Former [2021/52]AT31.03.2021
CZ31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
NL31.03.2021
PL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
Former [2021/51]AT31.03.2021
CZ31.03.2021
EE31.03.2021
ES31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
NL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
IS31.07.2021
PT02.08.2021
Former [2021/50]AT31.03.2021
CZ31.03.2021
EE31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
NL31.03.2021
RO31.03.2021
RS31.03.2021
SE31.03.2021
SK31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
PT02.08.2021
Former [2021/48]AT31.03.2021
CZ31.03.2021
EE31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
NL31.03.2021
RS31.03.2021
SE31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
Former [2021/47]AT31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
NL31.03.2021
RS31.03.2021
SE31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
Former [2021/46]AT31.03.2021
FI31.03.2021
HR31.03.2021
LT31.03.2021
LV31.03.2021
RS31.03.2021
SE31.03.2021
SM31.03.2021
BG30.06.2021
NO30.06.2021
Former [2021/38]FI31.03.2021
HR31.03.2021
LV31.03.2021
RS31.03.2021
SE31.03.2021
BG30.06.2021
NO30.06.2021
Former [2021/37]FI31.03.2021
HR31.03.2021
LV31.03.2021
RS31.03.2021
BG30.06.2021
NO30.06.2021
Former [2021/36]FI31.03.2021
HR31.03.2021
BG30.06.2021
NO30.06.2021
Former [2021/35]FI31.03.2021
HR31.03.2021
NO30.06.2021
Former [2021/33]FI31.03.2021
NO30.06.2021
Documents cited:Search[I]US2009123461  (FITZHUGH WILLIAM [US], et al) [I] 1-24 * See example 5 - Antibody development-, claims *;
 [I]  - PHIL OH, "Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung : Abstract : Nature Biotechnology", NATURE BIOTECHNOLOGY, (20070304), pages 327 - 337, XP055348188 [I] 1-24 * See § Methods, figures 1 & 6 *
International search[X]WO2007102787  (AGENCY SCIENCE TECH & RES [SG], et al);
 [Y]US7833733  (MCNAGNY KELLY M [CA], et al);
 [X]EP2452950  (ACTGEN INC [JP]);
 [X]  - CHOO A.B. ET AL., "Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1.", STEM CELLS., (20080320), vol. 26, no. 6, pages 1454 - 63, XP002538481

DOI:   http://dx.doi.org/10.1634/STEMCELLS.2007-0576
 [Y]  - LARSSON A. ET AL., "Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.", BRITISH JOURNAL OF CANCER., (20110809), vol. 105, no. 5, pages 666 - 672, XP055334827

DOI:   http://dx.doi.org/10.1038/bjc.2011.295
 [Y]  - HEUKAMP L.C. ET AL., "Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions.", HISTOPATHOLOGY., (20060705), vol. 49, no. 3, pages 242 - 247, XP055334829

DOI:   http://dx.doi.org/10.1111/j.1365-2559.2006.02489.x
ExaminationEP2452950
    - KIMBERLY A SNYDER ET AL, "Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy", BREAST CANCER RESEARCH, CURRENT MEDICINE GROUP LTD, GB, (20150327), vol. 17, no. 1, doi:10.1186/S13058-015-0562-7, ISSN 1465-5411, pages 1 - 14, XP021221754

DOI:   http://dx.doi.org/10.1186/s13058-015-0562-7
by applicantUS2009123461
 US2010061978
 US7833733
    - NIELSEN JS; MCNAGNY KM, J of Cell Science, (20080000), vol. 121, pages 3682 - 3692
    - DOYONNAS R. et al., J Exp Med, (20010000), vol. 194, no. 1, pages 13 - 27
    - NIELSEN JS; MCNAGNY KM, J Am Soc Nephrol, (20090000), vol. 20, no. 10, pages 1669 - 76
    - SOMASIRI A et al., Cancer Res, (20040000), vol. 64, no. 15, pages 5068 - 73
    - SOMASIRI et al., Cancer Res., (20040801), vol. 64, no. 15, pages 5068 - 73
    - THOMAS SN et al., Am J Physiol Cell Physiol, (20090300), vol. 296, no. 3, pages C505 - 13
    - KONSTANTOPOULOS K et al., Annu Rev Biomed Eng, (20090000), vol. 11, pages 177 - 202
    - THOMAS SN et al., Biorheology, (20090000), vol. 46, no. 3, pages 207 - 25
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.